With over 25 years‘ experience, HOF Sonderanlagenbau GmbH is the leading specialist in the manufacture of individual freeze drying systems, loading and unloading systems, as well as freeze-thaw units for the pharmaceutical and biotechnological industry. At our company location in Lohra, near Marburg, Germany, highly motivated and specially qualified employees work on the company‘s own production floor of some 12,500m2. A flexible service team keeps close contact with our customers, both nationally and internationally, providing support for the users of HOF systems.


In the pharmaceutical and biotechnological environment, quality and reliability are the decisive parameters in determining whether a company will be successful or not. This is guaranteed by using HOF‘s customized systems, but also because the company‘s systems technology is developed with an eye on the requirements of the future. The company, a specialist in individual solutions since its founding, distinguishes itself by offering only the highest quality in all stages: from the idea to the fully developed plan, all the way to the scrupulous manufacture of the system, which is customized and convincingly reliable. HOF systems are always a good investment for the future.


You are welcome to watch our Corporate Video on our homepage.

TECHNOLOGY

At HOF, it isn‘t technology which determines the product - it‘s the product properties which determine the technology. We rely on the most modern technological advances in our facilities and systems so we can provide our customers with excellent results, as reliably and as efficiently as possible. These technological advances include, for example, recipe-controlled automatic shelf adjustment, the use of PAT sensor technology, comparative pressure measurement and our controlled nucleation method ‘SYNCHROFREEZE’.

INNOVATION

Future-proof, high-performance and practice-oriented – these are the decisive parameters by which HOF systems measure themselves. The company is well-known for creative products which are developed to satisfy customer requirements using the latest technologies. Innovative solutions and individual designs help our customers to successfully achieve their goals.

CONSULTING

A team of experienced employees will give you individual advice from the very beginning of a project and accompany you as a partner through all processes up to the point when the system is working successfully. You can rely on employees who were trained especially for this task by HOF.

MANUFACTURE

Our dominant position compels us to be consistently excellent in our performance, high quality and farsightedness when developing trendsetting technologies. All HOF systems are manufactured and inspected fully by our employees at our production sites. This way we are able to guarantee the highest standards of quality. 

QUALITY

With every HOF system, our goal is only achieved when the result fully meets your expectations, not to 99%, but to the full 100%. For HOF, quality is the highest measure of things, and that applies to all areas, from the concept all the way to service – you can count on that!

EXPERTISE

The knowledge, ability and experience of our employees form the basis of our work. Decisive investments in our future are comprehensive training and a continual transfer of knowledge, which ensures that our highly qualified employees have wide-ranging expertise and can identify themselves with the products of HOF. This large set of skills gives you the security of knowing you‘ve made the right choice, which you can rely on during everyday production. 

Go to article: Home | Improving safety for multiple drug regimes Go to article: In this issueGo to article: ContentsGo to article: Curtis Health CapsGo to article: Astrix Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: CommentGo to article: Use of AI in the fight against Covid-19 shows mixed results Go to article: What does Ireland’s tax hike mean for pharma?Go to article: Chinese review designations lag behind US and EUGo to article: The business benefits of text mining in life sciencesGo to article: Mettler ToledoGo to article: HOF SonderanlagenbauGo to article: In DepthGo to article: Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbsGo to article: The challenges of multiple drugs safety reportingGo to article: 3D printing in drug manufacturing: unlocking future possibilitiesGo to article: Can drug repurposing uncover better treatments for UTIs?Go to article: Pfizer and Takeda deals put a spotlight on value-based pricing Go to article: Lethal injection: can pharma kill the death penalty?Go to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DataGo to article: Middle-income countries’ healthcare sectors to keep rising through to 2024Go to article: Data analytics hiring levels in clinical trial operations rose in OctoberGo to article: Industrial automation innovation in pharma rebounded in the last quarterGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: YearbookGo to article: SHL MedicalGo to article: Dr. Paul Lohmann Company Insight Go to article: Dr. Paul LohmannGo to article: Novo NordiskGo to article: NiproGo to article: EventsGo to article: Next issue